Zymeworks Solidifies Leadership Team with Key Appointments
Event summary
- Zymeworks appointed Adam Schayowitz as Head of R&D and Scott Platshon as Chief Business Officer on April 9, 2026.
- Both executives transitioned from interim roles to full-time positions, reporting directly to CEO Kenneth Galbraith.
- Schayowitz brings nearly two decades of oncology drug development experience to advance Zymeworks’ clinical pipeline.
- Platshon will lead the company’s asset aggregation strategy and manage cash flows from licensed healthcare assets.
The big picture
Zymeworks’ leadership appointments come as the company focuses on executing across its pipeline, partnerships, and broader corporate strategy. The moves underscore a shift toward balancing internal R&D innovation with strategic asset management, reflecting broader industry trends in biotech where companies are increasingly leveraging external collaborations to drive growth. With key milestones like the Phase 1 study initiation for ZW251 and expanding global approvals of zanidatamab, Zymeworks is positioning itself to optimize future cash flows while advancing its differentiated therapeutic platforms.
What we're watching
- Pipeline Execution
- How Schayowitz’s oncology expertise will accelerate Zymeworks’ clinical development and unlock additional value.
- Asset Strategy
- Whether Platshon can sustain the company’s asset aggregation strategy to drive long-term shareholder returns.
- Partnership Dynamics
- The pace at which Zymeworks integrates partnerships and collaborations into its R&D pipeline.
Related topics